BRPI0406667A - Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg - Google Patents

Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg

Info

Publication number
BRPI0406667A
BRPI0406667A BR0406667-7A BRPI0406667A BRPI0406667A BR PI0406667 A BRPI0406667 A BR PI0406667A BR PI0406667 A BRPI0406667 A BR PI0406667A BR PI0406667 A BRPI0406667 A BR PI0406667A
Authority
BR
Brazil
Prior art keywords
acceptable formulation
treating cancer
therapeutically acceptable
cancer
administered
Prior art date
Application number
BR0406667-7A
Other languages
English (en)
Portuguese (pt)
Inventor
George Tidmarsh
Original Assignee
Threshold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Threshold Pharmaceuticals Inc filed Critical Threshold Pharmaceuticals Inc
Publication of BRPI0406667A publication Critical patent/BRPI0406667A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0406667-7A 2003-01-10 2004-01-09 Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg BRPI0406667A (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US43926603P 2003-01-10 2003-01-10
US45866503P 2003-03-28 2003-03-28
US45884603P 2003-03-28 2003-03-28
US46001203P 2003-04-02 2003-04-02
US49616303P 2003-08-18 2003-08-18
PCT/US2004/000530 WO2004062604A2 (en) 2003-01-10 2004-01-09 Treatment of cancer with 2-deoxyglucose

Publications (1)

Publication Number Publication Date
BRPI0406667A true BRPI0406667A (pt) 2005-12-20

Family

ID=32719656

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406667-7A BRPI0406667A (pt) 2003-01-10 2004-01-09 Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg

Country Status (11)

Country Link
US (2) US6979675B2 (https=)
EP (1) EP1587519A4 (https=)
JP (1) JP2006515883A (https=)
KR (1) KR20050098244A (https=)
AU (1) AU2004204778B2 (https=)
BR (1) BRPI0406667A (https=)
CA (1) CA2513399A1 (https=)
IL (1) IL169594A0 (https=)
MX (1) MXPA05007382A (https=)
NO (1) NO20053782L (https=)
WO (1) WO2004062604A2 (https=)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US7381413B1 (en) * 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
EP1205493A1 (en) * 2000-11-14 2002-05-15 ATOFINA Research Polymerisation catalyst systems and their preparation
US7666459B2 (en) * 2001-09-12 2010-02-23 The Procter & Gamble Company Pet food compositions
US7547673B2 (en) * 2001-09-13 2009-06-16 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
EP1599196A4 (en) * 2003-01-17 2006-05-31 Threshold Pharmaceuticals Inc COMBINATION THERAPIES FOR CANCER TREATMENT
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7510710B2 (en) * 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
NZ549605A (en) * 2004-02-06 2010-01-29 Threshold Pharmaceuticals Inc Use of glufosfamide to treat chemotherapy-refractory pancreatic cancer
US20090252834A1 (en) * 2004-05-10 2009-10-08 Michael Griffin Hayek Compositions comprising glucose anti-metabolites
KR20070034591A (ko) 2004-06-17 2007-03-28 위스콘신 얼럼나이 리서어치 화운데이션 발작 및 발작병을 치료하기 위한 화합물 및 방법
WO2006024492A2 (en) * 2004-08-30 2006-03-09 Interstitial Therapeutics Medical implant provided with inhibitors of atp synthesis
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7740875B2 (en) * 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
KR20070085677A (ko) * 2004-11-02 2007-08-27 콘포마 세러퓨틱스 코포레이션 만성 림프성 백혈병의 치료 방법 및 치료 조성물
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR20070114753A (ko) * 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
WO2006091790A1 (en) 2005-02-23 2006-08-31 Xenoport, Inc. Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use
WO2006108679A2 (en) 2005-04-15 2006-10-19 Biomac Privatinstitut Für Medizinische Und Zahnmedizinische Forschung, Entwicklung Und Diagnostik Gmbh Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer
EP2261323A1 (en) 2005-05-31 2010-12-15 The Iams Company Feline probiotic lactobacilli
AU2006253007B2 (en) 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
US20060287253A1 (en) * 2005-06-17 2006-12-21 Kriegler Steven M Compounds and methods for treating seizure disorders
EP1902732A4 (en) * 2005-06-24 2009-07-22 Takeda Pharmaceutical PROPHYLACTIC / THERAPEUTIC AGENT AGAINST HER2-EXPRESSIVE CANCER
US20070032383A1 (en) * 2005-07-27 2007-02-08 Newell M K Systems, methods, and compositions for modifying the metabolism of plants and of euucaryotic microbes
US20070134349A1 (en) * 2005-09-19 2007-06-14 Duke University Methods of treating hematological malignancies
WO2007064448A2 (en) * 2005-11-28 2007-06-07 Ramot At Tel Aviv University, Ltd. Cancer treatment using fts and 2-deoxyglucose
WO2007067516A2 (en) * 2005-12-06 2007-06-14 Duke University Multiple myeloma
US7754693B2 (en) * 2006-02-16 2010-07-13 Young Hee Ko Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
US8022042B2 (en) * 2006-02-16 2011-09-20 Young Hee Ko Composition and methods for the treatment of cancer
US8324175B2 (en) 2006-02-16 2012-12-04 Young Hee Ko Compositions and methods for the treatment of cancer
BRPI0708273A2 (pt) * 2006-02-24 2011-05-24 Univ Texas uso de compostos de hexoses
WO2007100728A2 (en) * 2006-02-24 2007-09-07 University Of Miami Mannose derivatives for killing tumor cells
US9149489B2 (en) * 2006-04-27 2015-10-06 Board Of Regents, University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
WO2009108926A1 (en) * 2008-02-29 2009-09-03 Board Of Regents, The University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
AU2007246077A1 (en) * 2006-05-03 2007-11-08 I.Q.A., A.S. Pharmaceutical composition containing taxane derivative destined for the preparation of an infusion solution, method of preparation thereof and use thereof
EP2161332B1 (en) 2006-11-20 2015-04-22 National University Corporation Kagawa University Deoxyketohexose isomerase and method for producing deoxyhexose and derivative thereof using same
US20100203110A1 (en) * 2006-12-18 2010-08-12 The Johns Hopkins University Therapeutics for Cancer Using 3-Bromopyruvate and Other Selective Inhibitors of ATP Production
RU2436581C2 (ru) 2007-02-01 2011-12-20 Дзе Иамс Компани Способ уменьшения воспаления и снижения стресса у млекопитающего
EP2156188B1 (en) 2007-03-28 2021-05-05 University of Southern California Induction of differential stress resistance and uses thereof
US8865646B2 (en) * 2007-03-28 2014-10-21 University Of South California Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging
RU2349271C2 (ru) * 2007-03-29 2009-03-20 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ лечения рака прямой кишки
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US8765690B2 (en) * 2007-04-05 2014-07-01 Threshold Pharmaceuticals, Inc. Treatment of cancer with glufosfamide in patients not receiving insulin therapy
WO2009102986A1 (en) * 2008-02-15 2009-08-20 Catholic Healthcare West (D/B/A St. Joseph's Hospital And Medical Center) Treatment of adenocarcinoma expressing lkb1 with mtor inhibitor in combination with cox1 inhibitor
CA2716321A1 (en) 2008-02-21 2009-08-27 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
WO2009135181A2 (en) 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2009143515A2 (en) * 2008-05-23 2009-11-26 University Of Miami Treatment using continuous low dose application of sugar analogs
WO2009143611A1 (en) * 2008-05-27 2009-12-03 Oncolytics Biotech Inc. Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
ES2628180T3 (es) 2008-07-11 2017-08-02 Board Of Regents, The University Of Texas System Nuevos acetatos de 2-desoxi monosacáridos con actividad anticancerosa
WO2010008554A2 (en) * 2008-07-14 2010-01-21 The Regents Of The University Of Colorado Methods and products for treating proliferative diseases
US20110207680A1 (en) * 2008-08-13 2011-08-25 Curd John G Administration of Glufosfamide For The Treatment of Cancer
WO2010021750A2 (en) * 2008-08-21 2010-02-25 The Johns Hopkins University Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20120121515A1 (en) 2009-03-13 2012-05-17 Lenny Dang Methods and compositions for cell-proliferation-related disorders
TWI598337B (zh) 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US8450090B2 (en) 2009-10-06 2013-05-28 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for promoting fatty acid production in plants
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
EP2525790B1 (en) 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
PT3095458T (pt) 2009-10-22 2018-11-09 Propanc Pty Ltd Composição farmacêutica para tratar cancro compreendendo tripsinogénio e quimiotripsinogénio
CN102115483B (zh) 2009-12-30 2014-12-17 苏州天人合生物技术有限公司 卤代双去氧糖衍生物及其制备方法与应用
GB2478556A (en) * 2010-03-09 2011-09-14 Myrovlytis Technology Ventures Ltd A composition for use in the treatment of Birt-Hogg-Dubô sydrome
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
RU2625768C2 (ru) 2010-08-05 2017-07-18 Сиэтл Дженетикс, Инк. Способы ингибирования фукозилирования белков in vivo с использованием аналогов фукозы
BR112013009086A2 (pt) 2010-10-13 2016-07-26 Mustafa Bilgin Ali Djamgoz tratamento de câncer/inibição de metástase
WO2012049439A1 (en) * 2010-10-13 2012-04-19 Imperial Innovations Limited Treatment of cancer/inhibition of metastasis
WO2012097052A2 (en) * 2011-01-11 2012-07-19 Intertech Bio, Llc Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
WO2012123774A1 (en) * 2011-03-11 2012-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Glycolytic inhibitor with cytotoxic agent for use in the treatment of a cancer
US20120238511A1 (en) * 2011-03-14 2012-09-20 University Of Southern California 2-deoxy-d-glucose formulations for prevention or treatment of neurodegenerative diseases
SMT202400081T1 (it) 2011-05-03 2024-03-13 Agios Pharmaceuticals Inc Attivatori della piruvato chinasi per uso in terapia
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
EP2739971A1 (en) * 2011-08-02 2014-06-11 Roche Diagnostics GmbH In vitro tumor metastasis model
KR101900478B1 (ko) * 2011-08-04 2018-09-20 한올바이오파마주식회사 암의 재발 또는 전이의 억제용 약제학적 조성물
PE20142098A1 (es) 2012-01-06 2015-01-08 Agios Pharmaceuticals Inc Compuestos terapeuticamente activos y sus metodos de uso
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2013123151A1 (en) * 2012-02-14 2013-08-22 The Wistar Institute Of Anatomy And Biology Methods of controlling tumor bioenergetics networks
AU2013202693B2 (en) * 2012-04-16 2015-01-22 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics
US10350228B2 (en) 2012-08-23 2019-07-16 Seattle Genetics, Inc. Treatment of sickle cell disease and inflammatory conditions
EP2906212A4 (en) 2012-10-15 2016-06-08 Agios Pharmaceuticals Inc THERAPEUTIC COMPOUNDS AND COMPOSITIONS
WO2014072967A1 (en) * 2012-11-12 2014-05-15 Urifer Ltd Drug combination comprising a glycolysis inhibitor and a tyrosine kinase inhibitor
KR101419816B1 (ko) * 2013-01-30 2014-07-17 (주)제욱 상승적 치료 효과를 갖는 비소세포폐암의 예방 또는 치료용 조성물
PL2981270T3 (pl) 2013-04-05 2022-05-09 Board Of Regents, The University Of Texas System Estry 2-deoksy-monosacharydów o działaniu przeciwproliferacyjnym
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015108933A1 (en) 2014-01-14 2015-07-23 The Johns Hopkins University Cyclodextrin compositions encapsulating a selective atp inhibitor and uses thereof
NZ723859A (en) 2014-03-14 2023-01-27 Servier Lab Pharmaceutical compositions of therapeutically active compounds and their uses
WO2016065353A1 (en) * 2014-10-24 2016-04-28 University Of Miami Combination therapy with fenofibrate and 2-deoxyglucose or 2-deoxymannose
CA2989111C (en) 2015-06-11 2023-10-03 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
FI3362065T3 (fi) 2015-10-15 2024-06-19 Servier Lab Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi
KR102699521B1 (ko) 2015-10-15 2024-08-26 르 라보레또레 쎄르비에르 악성 종양의 치료를 위한 조합물 요법
US10751306B2 (en) 2015-11-06 2020-08-25 The Johns Hopkins University Methods of treating liver fibrosis by administering 3-bromopyruvate
US12419938B2 (en) 2015-11-12 2025-09-23 Propanc Pty Ltd Proenzyme composition
CN108697771A (zh) 2016-01-29 2018-10-23 普罗潘克股份有限公司 癌症治疗
WO2017173360A2 (en) * 2016-03-31 2017-10-05 Stcube, Inc. Combination treatments directed toward programmed death ligand-1 (pd-l1) positive cancers
JP6888239B2 (ja) 2017-06-28 2021-06-16 株式会社 ＳＥＮＴＡＮ Ｐｈａｒｍａ 腫瘍治療用腫瘍免疫活性促進剤及び腫瘍治療用医薬組成物
MX2020000734A (es) 2017-07-21 2020-07-29 Buck Inst Res Aging Enantiómeros s de beta-hidroxibutirato y butanodiol, y métodos para usarlos.
WO2019147503A1 (en) 2018-01-25 2019-08-01 Buck Institute For Research On Aging Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US20210196701A1 (en) 2018-05-16 2021-07-01 Forma Therapeutics, Inc. Inhibiting mutant idh-1
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
RU2707554C1 (ru) * 2019-02-27 2019-11-28 Федеральное государственное бюджетное учреждение "Петербургский институт ядерной физики им. Б.П. Константинова Национального исследовательского центра "Курчатовский институт" (НИЦ "Курчатовский институт-ПИЯФ") Композиция, ингибирующая рост и выживаемость опухолевых клеток
BR112022018536A2 (pt) 2020-03-16 2022-11-29 Univ Texas Método para o tratamento de infecções virais com monossacarídeos tipo hexose e seus análogos
WO2021211609A1 (en) * 2020-04-16 2021-10-21 Buck Institute For Research On Aging Treatment of viral pathologies with exogenous ketones
JP2023554188A (ja) * 2020-12-14 2023-12-26 トリム バイオテック，エセ．エレ． 癌免疫療法のための細菌を含む組成物
WO2023062516A1 (en) * 2021-10-11 2023-04-20 Exploration Invest Pte Ltd 2-deoxy-d-glucose for use in disease therapy
CN114617876B (zh) * 2022-01-28 2023-04-07 四川大学华西医院 一种抗肿瘤联合用药物
KR20240038394A (ko) 2022-09-16 2024-03-25 이화여자대학교 산학협력단 해당과정 억제제 및 미토콘드리아 기능 억제제를 포함하는 암의 예방 또는 치료용 약학적 조성물
EP4582080A1 (en) 2024-01-02 2025-07-09 G.ST Antivirals GmbH Dispenser for mucosal administration comprising 2-deoxy-glucose or analogues thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS606630B2 (ja) 1977-09-07 1985-02-19 藤沢薬品工業株式会社 ２―デオキシ―ｄ―グルコースの製造法
US4315001A (en) 1979-08-17 1982-02-09 Blough Herbert A 2-Deoxy glucose as an antiviral agent against herpes simplex
US5185325A (en) 1988-06-23 1993-02-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic composition
EP0565785A1 (en) 1992-04-07 1993-10-20 Harry H. Leveen Use of glucose transport inhibitors for the treatment for acne
KR950009111B1 (ko) * 1992-09-08 1995-08-14 주식회사럭키 광택 조절용 수지의 제조방법
US5591429A (en) * 1993-07-26 1997-01-07 The United States Of America As Represented By The Secretary Of Agriculture Composition containing 2-deoxy-D-glucose and Candida saitoana and a method of use for the biological control of postharvest diseases
US5643883A (en) 1995-01-19 1997-07-01 Uab Research Foundation Glucose-6-phosphate uptake inhibitors and novel uses thereof
DE19524515A1 (de) 1995-07-05 1997-01-09 Deutsches Krebsforsch Saccharid-Konjugate
US5652273A (en) 1995-11-30 1997-07-29 Henry; James Reduction of hair growth
US5565434A (en) 1996-02-23 1996-10-15 University Of Iowa Research Foundation Hexose and pentose prodrugs of ethacrynic acid
US5958892A (en) * 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US20020035071A1 (en) 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
GR1003713B (el) 1998-03-20 2001-11-07 Δεσοξυσακχαρα ως αντικαρκινικοι αναχαιτιστικοι παραγοντες.
US20030072814A1 (en) 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts
US6670330B1 (en) * 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
US6974664B2 (en) 2000-05-12 2005-12-13 The Board Of Trustees Of The Leland Stanford University Screening method for cancer therapeutics and stable antitumor drug
WO2002058741A2 (en) 2000-12-18 2002-08-01 Alex Wah Hin Yeung Treatment of cancer with positron-emitting radiopharmaceuticals
US6661410B2 (en) * 2001-09-07 2003-12-09 Microsoft Corporation Capacitive sensing and data input device power management

Also Published As

Publication number Publication date
EP1587519A4 (en) 2006-05-31
AU2004204778A1 (en) 2004-07-29
KR20050098244A (ko) 2005-10-11
CA2513399A1 (en) 2004-07-29
WO2004062604A2 (en) 2004-07-29
US20040167079A1 (en) 2004-08-26
JP2006515883A (ja) 2006-06-08
NO20053782D0 (no) 2005-08-09
MXPA05007382A (es) 2005-11-23
EP1587519A2 (en) 2005-10-26
NO20053782L (no) 2005-09-27
US6979675B2 (en) 2005-12-27
AU2004204778B2 (en) 2008-05-22
IL169594A0 (en) 2007-07-04
US20050245462A1 (en) 2005-11-03
WO2004062604A3 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
BRPI0406667A (pt) Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg
NO20014842D0 (no) Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft
Disa et al. Prevention of adriamycin-induced full-thickness skin loss using hyaluronidase infiltration
WO2004064734A3 (en) Combination therapies for the treatment of cancer
BR0113447A (pt) Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
BR0110877A (pt) Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
Loth et al. Treatment methods for extravasations of chemotherapeutic agents: a comparative study
BR0116862A (pt) Medicamento, métodos para tratar um paciente com osteonecrose e/ou osteocondrite dissecans, para prevenir a osteonecrose e/ou osteocondrite dissecans em um paciente em risco de cada uma das ditas doenças, uso de um medicamento, e, método para prevenir a destruição da cartilagem ou condrólise associadas com osteonecrose e/ou osteocondrite dissecans
BR0315573A (pt) Método para tratar, prevenir, controlar e/ou modificar dor em um paciente e composição farmacêutica
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
CY1107352T1 (el) Προεγχειρητικη θεραπευτικη αγωγη μετεγχειρητικου πονου
BRPI0413410A (pt) co-administração de um polissacarìdeo com um agente quimioterapêutico para o tratamento de cáncer
Maniar et al. Does postoperative intravenous ferric carboxymaltose hasten the recovery of hemoglobin in patients post total knee arthroplasty?
TW200420290A (en) Methods for the treatment, prevention and management of macular degeneration
Schulmeister Totect™: A new agent for treating anthracycline extravasation
Cicchetti et al. Two case reports of vinorelbine extravasation: management and review of the literature
BR0315609A (pt) Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica
BRPI0404050A (pt) Uso de um composto ou de um seu sal ou éster farmaceuticamente aceitável, formulação farmacêutica, formulação acondicionada, composto, e, método para prevenir e/ou tratar hiperplasia benigna da próstata em pacientes em necessidade de tal prevenção ou tratamento
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
BRPI0412408A (pt) métodos para a produção de um efeito de redução antiangiogênico e/ou de permeabilidade vascular e para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, composição farmacêutica, kit, e uso de azd2171 ou um sal farmaceuticamente aceitável deste e zd1839 ou um sal farmaceuticamente aceitável deste
BRPI0416266A (pt) método para tratar, prevenir e/ou controlar uma doença ou distúrbio relacionada com amianto em um paciente
WO2001054678A3 (en) Combination therapy for cancer
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.